Shareholder Votes

Ulta Beauty, Inc. shareholders approved Ratification of the appointment of Ernst & Young LLP as the company's independent registered public accounting firm for fiscal 2026. at the 2026-06-09 meeting.

“The stockholders ratified the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for its fiscal year 2026, ending January 30, 2027. The results of the vote were as follows: For Against Abstain Votes Percentage (1) Votes Percentage (1) Votes Percentage (1) 33,540,095 88.08% 4,500,462 11.82% 40,566 0.11%”

Ulta Beauty, Inc. shareholders approved Approve an amendment to the company's certificate of incorporation to limit officer liability as permitted by Delaware law (Exculpation Amendment). at the 2026-06-09 meeting.

“The stockholders approved the Exculpation Amendment. The results of the vote were as follows: For Against Abstain Broker Non-Votes Votes Percentage (3) Votes Percentage (3) Votes Percentage (3) Votes Percentage 30,394,172 69.77% 4,878,646 11.20% 43,103 0.10% 2,765,202 N/A”

Ulta Beauty, Inc. shareholders approved Election of Martin Brok, Kelly E. Garcia, Catherine A. Halligan, Stephenie Landry, Patricia A. Little, George R. Mrkonic, Lorna E. Nagler, Gisel Ruiz, Michael C. Smith, and Kecia L. Steelman as directors to hold office until the 2027 annual meeting of stockholders. at the 2026-06-09 meeting.

“The stockholders elected Martin Brok, Kelly E. Garcia, Catherine A. Halligan, Stephenie Landry, Patricia A. Little, George R. Mrkonic, Lorna E. Nagler, Gisel Ruiz, Michael C. Smith, and Kecia L. Steelman as directors to hold office until the 2027 annual meeting of stockholders. The results of the vote were as follows: For Against Abstain Broker Non-Votes Name Votes Percentage (1) Votes Percentage (1) Votes Percentage (2) Votes Percentage (2) Martin Brok 34,753,758 98.50% 528,513 1.50% 33,650 N/A 2,765,202 N/A Kelly E. Garcia 34,755,399 98.51% 527,459 1.49% 33,063 N/A 2,765,202 N/A Catherine A. Halligan 34,377,238 97.43% 906,108 2.57% 32,575 N/A 2,765,202 N/A Stephenie Landry 34,776,079 98.57% 505,443 1.43% 33,399 N/A 2,765,202 N/A Patricia A. Little 34,674,997 98.28% 608,490 1.72% 32,434 N/A 2,765,202 N/A George R. Mrkonic 34,720,104 98.41% 562,487 1.59% 33,330 N/A 2,765,202 N/A Lorna E. Nagler 33,238,507 94.21% 2,044,509 5.79% 32,905 N/A 2,765,202 N/A Gisel Ruiz 33,383,704 94.62% 1,89”

Fusemachines Inc. shareholders approved Ratify the appointment of KNAV CPA LLP as the independent registered public accounting firm of the Company for the fiscal year ending December 31, 2026. at the 2026-06-09 meeting.

“Proposal 3: Ratification of the appointment of KNAV CPA LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026.”

Fusemachines Inc. shareholders approved Approve an amendment to the Company's 2025 Omnibus Equity Incentive Plan, as amended, to increase the maximum number of shares of common stock available to Plan participants thereunder by 2,000,000 shares to an aggregate of 3,500,000 shares. at the 2026-06-09 meeting.

“Proposal 2: Approval of the amendment to the Company's 2025 Omnibus Equity Incentive Plan, as amended, to increase the maximum number of shares of common stock available to Plan participants thereunder by 2,000,000 shares to an aggregate of 3,500,000 shares.”

Fusemachines Inc. shareholders approved Election of three Class I directors: Bharat Krish, Tim Gocher, and Salman Alam at the 2026-06-09 meeting.

“Elect Salman Alam, Bharat Krish, and Tim Gocher, as Class I directors to serve for a term of three years or until such director's successor is duly elected and qualified or until such director's earlier death, resignation, disqualification or removal.”

Lovesac Co shareholders approved Ratification of the appointment of Deloitte & Touche LLP as independent auditor for the Company for the fiscal year ending January 31, 2027. at the 2026-06-09 meeting.

“PROPOSAL 3 - Ratification of the appointment of Deloitte & Touche LLP as independent auditor for the Company for the fiscal year ending January 31, 2027. For Against Abstain Broker Non-Vote 11,204,442 36,480 7,485 0”

Lovesac Co shareholders approved Advisory approval of the Company's fiscal 2026 compensation for its named executive officers. at the 2026-06-09 meeting.

“PROPOSAL 2 - Advisory approval of the Company's fiscal 2026 compensation for its named executive officers. For Against Abstain Broker Non-Vote 6,759,080 2,563,546 2,954 1,922,827”

Lovesac Co shareholders approved Election of eight directors at the 2026-06-09 meeting.

“PROPOSAL 1 - Election of eight (8) directors . For Withhold Broker Non-Vote Alan Boehme 9,308,778 16,802 1,922,827 Andrew Heyer 6,937,893 2,387,687 1,922,827 Sharon Leite 7,989,365 1,336,215 1,922,827 Wan Ling Martello 9,314,084 11,496 1,922,827 Walter McLallen 8,003,837 1,321,743 1,922,827 Vineet Mehra 8,012,726 1,312,854 1,922,827 Shawn Nelson 9,307,843 17,737 1,922,827 Shirley Romig 8,004,439 1,321,141 1,922,827”

Lafayette Square USA, Inc. shareholders approved Ratification of selection of Ernst & Young LLP as independent registered public accounting firm for fiscal year ending December 31, 2026 at the 2026-06-03 meeting.

“Votes For Votes Against Abstentions Broker Non-Votes 21,530,729 0 1,138,021 0”

Lafayette Square USA, Inc. shareholders approved Election of Class II Directors at the 2026-06-03 meeting.

“Name Votes For Votes Against Broker Non-Votes Sashi Brown 21,530,729 0 0 Jamila Mayfield 21,530,729 0 0”

INNOVATIVE INDUSTRIAL PROPERTIES INC shareholders approved Adoption of the Innovative Industrial Properties, Inc. 2026 Omnibus Incentive Plan at the 2026-06-09 meeting.

“the stockholders approved the Innovative Industrial Properties, Inc. 2026 Omnibus Incentive Plan (the "2026 Plan"), which replaces the previously existing Innovative Industrial Properties, Inc. 2016 Omnibus Incentive Plan (the "Prior Plan")”

Relay Therapeutics, Inc. shareholders approved Approval of amendment to the Fourth Amended and Restated Certificate of Incorporation to increase authorized shares of common stock from 300,000,000 to 450,000,000 at the 2026-06-09 meeting.

“The Company’s stockholders approved an amendment to the Company’s Fourth Amended and Restated Certificate of Incorporation, as amended, to increase the number of authorized shares of common stock from 300,000,000 shares to 450,000,000 shares, with the votes cast as follows: Votes For Votes Against Abstain Broker Non-Votes 170,323,683 909,020 23,821 0”

Relay Therapeutics, Inc. shareholders approved Ratification of appointment of Ernst & Young LLP as independent registered public accounting firm for fiscal year ending December 31, 2026 at the 2026-06-09 meeting.

“The Company’s stockholders ratified the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026, with the votes cast as follows: Votes For Votes Against Abstain Broker Non-Votes 171,030,133 204,449 21,942 0”

Relay Therapeutics, Inc. shareholders approved Non-binding advisory vote on executive compensation at the 2026-06-09 meeting.

“The Company’s stockholders approved, on a non-binding, advisory basis, the compensation of the Company’s named executive officers, with the votes cast as follows: Votes For Votes Against Abstain Broker Non-Votes 143,849,919 3,154,118 51,787 24,200,700”

Relay Therapeutics, Inc. shareholders approved Election of class III directors for a three-year term ending at the 2029 annual meeting at the 2026-06-09 meeting.

“The Company’s stockholders elected each of the following individuals to serve as class III directors for a three-year term ending at the Company’s 2029 annual meeting of stockholders and until his or her respective successor is duly elected and qualified, or until his or her earlier death, resignation or removal, with the votes cast as follows: Name Votes For Votes Withheld Broker Non-Votes Douglas S. Ingram 120,859,999 26,195,825 24,200,700 Claire Mazumdar, Ph.D. 122,859,060 24,196,764 24,200,700”

Payoneer Global Inc. shareholders approved Non-Binding Advisory Vote to Approve Named Executive Officer Compensation at the 2026-06-09 meeting.

“Proposal 3 – Non-Binding Advisory Vote to Approve Named Executive Officer Compensation The compensation paid to our named executive officers was approved on a non-binding, advisory basis by stockholders with 183,709,751 shares voted in favor, 16,478,407 shares voted against, and 98,953 shares abstained. The proposal also had broker non-votes totaling 66,992,499.”

Payoneer Global Inc. shareholders approved Ratification of Appointment of Independent Registered Public Accounting Firm at the 2026-06-09 meeting.

“Proposal 2 – Ratification of Appointment of Independent Registered Public Accounting Firm The earlier appointment by the Audit Committee of Kesselman & Kesselman, a member firm of PricewaterhouseCoopers International Limited, as the Company’s independent registered public accounting firm for the 2026 fiscal year was ratified by stockholders with 255,270,515 shares voted in favor, 6,708,995 shares voted against, and 5,300,100 shares abstained.”

Payoneer Global Inc. shareholders approved Election of Class II Directors at the 2026-06-09 meeting.

“Proposal 1 – Election of Directors The following Class II directors (the “Directors”) were elected to the Board of Directors of the Company with a tabulation of votes as shown below. The Directors also had broker non-votes totaling 66,992,499. Name For Against Abstained John Caplan 198,488,911 1,646,873 151,327 Amir Goldman 184,190,282 15,938,308 158,521 Susanna Morgan 199,342,951 816,166 127,994”

Alignment Healthcare, Inc. shareholders approved Say-on-Pay Vote on the executive compensation of the Company's named executive officers at the 2026-06-04 meeting.

“Proposal 3: Say-on-Pay Vote. On an advisory basis, the executive compensation of the Company’s named executive officers was approved based on the following votes: For Against Abstain Broker Non-Vote 169,068,300 8,701,941 542,191 15,800,560”

Alignment Healthcare, Inc. shareholders approved Ratification of the Appointment of Deloitte & Touche LLP as the independent registered public accounting firm for the Company for the fiscal year ending December 31, 2026 at the 2026-06-04 meeting.

“Proposal 2: Ratification of the Appointment of Deloitte & Touche LLP. The appointment of Deloitte & Touche LLP as the independent registered public accounting firm for the Company for the fiscal year ending December 31, 2026 was ratified based upon the following votes: For Against Abstain 194,030,577 13,893 68,522”

Alignment Healthcare, Inc. shareholders approved Election of Class II Directors at the 2026-06-04 meeting.

“Proposal 1: Election of Class II Directors. The three Class II directors were elected at the Annual Meeting based upon the following votes: Class I Director Name For Withhold Broker Non-Vote Jody Bilney 135,714,231 42,598,200 15,800,560 David Hodgson 108,386,550 69,925,881 15,800,560 Jacqueline Kosecoff 135,613,817 42,698,614 15,800,560”

Eton Pharmaceuticals, Inc. shareholders approved Ratification of the Appointment of Grant Thornton LLP as the Company's Independent Registered Public Accounting Firm for the year ending December 31, 2026 at the 2026-06-09 meeting.

“Proposal 2: Ratification of the Appointment of Grant Thornton LLP as the Company ’ s Independent Registered Public Accounting Firm for the year ending December 31, 2026 For Against Abstain 16,942,328 3,236,671 5,301”

Eton Pharmaceuticals, Inc. shareholders voted on Election of Directors at the 2026-06-09 meeting.

“Proposal 1: Election of Directors Nominee For Withheld Broker Non-Votes Jenn Adams 13,370,948 2,149,317 4,664,035 Charles J. Casamento 9,925,548 5,594,717 4,664,035”

ClearSign Technologies Corp shareholders approved The approval of one or more adjournments of the Annual Meeting to a later date or dates to solicit additional proxies if there are insufficient votes to approve the A&R 2021 Plan or in the absence of a quorum (the “Adjournment Proposal”). at the 2026-06-08 meeting.

“Proposal 5 . The approval of one or more adjournments of the Annual Meeting to a later date or dates to solicit additional proxies if there are insufficient votes to approve the A&R 2021 Plan or in the absence of a quorum (the “Adjournment Proposal”). For Against Abstentions Broker Non-Votes 1,596,167 570,671 46,426 1,453,588 The stockholders approved the Adjournment Proposal.”

ClearSign Technologies Corp shareholders approved The approval, on an advisory basis, of the compensation paid to the Company’s named executive officers. at the 2026-06-08 meeting.

“Proposal 4 . The approval, on an advisory basis, of the compensation paid to the Company’s named executive officers. For Against Abstentions Broker Non-Votes 1,826,151 379,205 7,908 1,453,588 The stockholders approved, on an advisory basis, the compensation paid to the Company’s named executive officers.”

ClearSign Technologies Corp shareholders approved The approval of the amended and restated ClearSign Technologies Corporation 2021 Equity Incentive Plan (the “A&R 2021 Plan”). at the 2026-06-08 meeting.

“Proposal 3 . The approval of the amended and restated ClearSign Technologies Corporation 2021 Equity Incentive Plan (the “A&R 2021 Plan”). For Against Abstentions Broker Non-Votes 1,546,015 659,279 7,970 1,453,588 The stockholders approved the A&R 2021 Plan.”

ClearSign Technologies Corp shareholders approved The approval, on an advisory basis, of the appointment of BPM CPA LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026. at the 2026-06-08 meeting.

“Proposal 2 . The approval, on an advisory basis, of the appointment of BPM CPA LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026. For Against Abstentions 3,263,437 394,510 8,905 There were no broker non-votes on this proposal. The stockholders approved, on an advisory basis, the appointment of BPM CPA LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026.”

ClearSign Technologies Corp shareholders approved Election of Directors at the 2026-06-08 meeting.

“Proposal 1 . Election of Directors. Nominee Name For Against Abstentions Broker Non-Votes Louis J. Basenese 1,808,414 370,481 34,369 1,453,588 Colin James Deller 1,995,376 217,011 877 1,453,588 Anthony DiGiandomenico 1,775,452 418,786 19,026 1,453,588 G. Todd Silva 1,829,493 364,781 18,990 1,453,588 Each of the four nominees standing for re-election as a director was elected to serve on the Company’s board of directors until the election and qualification of his successor or until his earlier death, resignation, or removal.”

XMax Inc. shareholders approved Advisory Vote on the Frequency of Future Advisory Votes on the Compensation of Named Executive Officers at the 2026-06-05 meeting.

“The results of the advisory, non-binding vote as to the frequency of the advisory vote on the compensation of named executive officers were as follows: 1 Year 2 Years 3 Years Abstain 12,468,727 2,083 417 121”

XMax Inc. shareholders approved Advisory Vote on the Compensation of Named Executive Officers at the 2026-06-05 meeting.

“The shareholders approved, on an advisory, non-binding basis, the compensation of our named executive officers as follows: For Against Abstain Broker Non-Votes 12,467,949 928 2,471 5,752,115”

XMax Inc. shareholders approved Approval and Ratification of the Appointment of Enrome LLP as the Company's Independent Registered Public Accounting Firm at the 2026-06-05 meeting.

“The shareholders approved and ratified the appointment of Enrome LLP. as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026, as follows: For Against Abstain Broker Non-Votes 18,214,504 7,189 1,770 N/A”

XMax Inc. shareholders approved Election of Directors at the 2026-06-05 meeting.

“The following six individuals were elected to the Board of Directors of the Company to serve as directors until the 2027 Annual Meeting of Shareholders and until their successors have been duly elected and qualified by votes as follows: Nominees Votes Cast For Votes Against Abstain Broker Non-Votes Umesh Patel 12,332,165 137,019 2,164 5,752,115 Xiaohua Lu 12,470,649 554 145 5,752,115 Yizhou (Steven) Zhao 12,451,556 19,647 145 5,752,115 Ming-Cherng Sky Tsai 12,404,876 66,327 145 5,752,115 Wen Tao 12,470,618 585 145 5,752,115 Matthew Beck 12,470,732 471 145 5,752,115”

Franklin BSP Realty Trust, Inc. shareholders approved Advisory Vote on the Compensation of the Company’s Named Executive Officers at the 2026-06-08 meeting.

“Proposal No. 3 - Advisory Vote on the Compensation of the Company’s Named Executive Officers: The proposal was approved. Votes For Votes Against Votes Abstained Broker Non-Votes 40,071,017 5,413,939 414,101 13,533,732”

Franklin BSP Realty Trust, Inc. shareholders approved Ratification of the Appointment of PwC as the Company’s Independent Registered Public Accounting Firm for the Fiscal Year Ending December 31, 2026 at the 2026-06-08 meeting.

“Proposal No. 2 - Ratification of the Appointment of PwC as the Company’s Independent Registered Public Accounting Firm for the Fiscal Year Ending December 31, 2026: The proposal was approved. Votes For Votes Against Votes Abstained Broker Non-Votes 58,612,929 616,987 202,873 --”

Franklin BSP Realty Trust, Inc. shareholders approved Election of Directors at the 2026-06-08 meeting.

“Proposal No. 1 - Election of Directors Each of the following directors was elected to hold office until the 2027 annual meeting of stockholders and until their successors are duly elected and qualified. Nominee Votes For Votes Against Votes Abstained Broker Non-Votes Pat Augustine 44,197,399 1,506,854 194,804 13,533,732 Richard J. Byrne 43,144,273 2,561,401 193,383 13,533,732 Joe Dumars 44,744,702 962,737 191,618 13,533,732 Peter J. McDonough 41,074,290 4,631,801 192,966 13,533,732 Buford H. Ortale 44,184,291 1,521,395 193,371 13,533,732 Elizabeth K. Tuppeny 42,266,447 3,445,989 186,621 13,533,732”

Humacyte, Inc. shareholders approved Approval of an Amendment to the Certificate of Incorporation to Increase the Number of Authorized Shares of Common Stock at the 2026-06-09 meeting.

“The stockholders approved the Amendment to increase the number of authorized shares of common stock from 350,000,000 shares to 550,000,000 shares.”

Humacyte, Inc. shareholders approved Ratification of the Selection of Independent Registered Public Accounting Firm at the 2026-06-09 meeting.

“The appointment of Pricewaterhouse Coopers LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026 was ratified.”

Humacyte, Inc. shareholders approved Approval of the Frequency of Future Advisory Votes on Named Executive Officer Compensation at the 2026-06-09 meeting.

“The stockholders approved, on an advisory basis, the holding of advisory vote to approve the compensation paid to the Company’s named executive officers on an annual basis.”

Humacyte, Inc. shareholders approved Approval of Named Executive Officer Compensation at the 2026-06-09 meeting.

“The stockholders approved, on an advisory basis, the compensation paid to the Company’s named executive officers, as described in the executive compensation section of the proxy statement.”

Humacyte, Inc. shareholders approved Election of Class II directors at the 2026-06-09 meeting.

“The stockholders elected each of the three Class II directors who were nominated to serve until the Company’s 2029 annual meeting of stockholders or until such director’s successor is elected, or until such director’s earlier death, resignation or removal.”

Adaptive Biotechnologies Corp shareholders approved Ratification of Ernst & Young LLP as the Company's independent registered public accounting firm for the year ending December 31, 2026 at the 2026-06-05 meeting.

“Proposal 3: Ramification of Ernst & Young LLP as the Company's Independent Registered Public Accounting Firm for the Year Ending December 31, 2026”

Adaptive Biotechnologies Corp shareholders approved Advisory request concerning compensation for the Company's 2025 named executive officers at the 2026-06-05 meeting.

“Proposal 2: an advisory request concerning compensation for the Company's 2025 named executive officers”

Adaptive Biotechnologies Corp shareholders approved Election of two Class I directors to the Board of Directors (Robert Hershberg, PhD, MD and Katey Owen, PhD) at the 2026-06-05 meeting.

“Proposal 1: election of two Class I directors to the Board of Directors (Robert Hershberg, PhD, MD and Katey Owen, PhD)”

Revolve Group, Inc. shareholders approved Advisory Vote on the Compensation of the Company's Named Executive Officers at the 2026-06-05 meeting.

“Based on the votes set forth below, the stockholders approved, on a non-binding advisory basis, the compensation of the Company's named executive officers.”

Revolve Group, Inc. shareholders approved Ratification of Appointment of Independent Registered Public Accounting Firm at the 2026-06-05 meeting.

“Based on the votes set forth below, the stockholders ratified the appointment of KPMG LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026.”

Revolve Group, Inc. shareholders approved Election of Directors at the 2026-06-05 meeting.

“Based on the votes set forth below, the stockholders elected the individuals listed below as directors to serve on the Board of Directors of the Company, each to serve until the 2027 annual meeting of stockholders or until his or her successor is duly elected and qualified or until his or her earlier death, resignation or removal.”

MoonLake Immunotherapeutics shareholders approved Approval of an Amendment and Restatement of the 2022 Equity Incentive Plan.

“Proposal 4. Approval of an Amendment and Restatement of the 2022 Equity Incentive Plan 50,599,032 498,186 14,146 10,761,142”

MoonLake Immunotherapeutics shareholders approved Advisory Vote on Executive Compensation.

“Proposal 3. Advisory Vote on Executive Compensation 50,365,168 731,158 15,038 10,761,142”

MoonLake Immunotherapeutics shareholders approved Ratification, by ordinary resolution, of Baker Tilly US, LLP as Independent Auditor.

“Proposal 2. Ratification, by ordinary resolution, of Baker Tilly US, LLP as Independent Auditor 61,831,463 17,522 23,521 0”